Review
Version 1
This version is not peer-reviewed
A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models and Anti-Viral Interventions
Sabarinath Neerukonda
Version 1
: Received: 11 May 2020 / Approved: 12 May 2020 / Online: 12 May 2020 (05:45:58 CEST)
How to cite: Neerukonda, S.; Katneni, U. A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models and Anti-Viral Interventions. Preprints 2020, 2020050204 (doi: 10.20944/preprints202005.0204.v1). Neerukonda, S.; Katneni, U. A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models and Anti-Viral Interventions. Preprints 2020, 2020050204 (doi: 10.20944/preprints202005.0204.v1).
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of CoV disease 2019 (COVID-19) is a highly pathogenic and transmissible CoV that is presently plaguing the global human population and economy. No proven effective anti-viral therapy or vaccine currently exist, and supportive care remains to be the cornerstone treatment. Through previous lessons learned from SARS-CoV-1 and MERS-CoV studies, scientific groups worldwide have rapidly expanded the knowledge pertaining to SARS-CoV-2 virology that included in vitro and in vivo models for testing of anti-viral therapies, and randomized clinical trials. In the present narrative, we review SARS-CoV-2 virology, clinical features, pathophysiology, and animal models with a specific focus on anti-viral and adjunctive therapies currently being tested or require testing in animal models and randomized clinical trials.
Subject Areas
SARS-CoV-2; COVID-19; animal models; anti-virals
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.
Leave a public commentSend a private comment to the author(s)